{
    "clinical_study": {
        "@rank": "67226", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomised to a treatment sequence consisting of 8 treatment periods"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will be randomised to a treatment sequence consisting of 8 treatment periods"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the\n      pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting\n      insulin aspart (FIAsp) in subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 18-64 years (both inclusive) at the time of signing informed\n             consent\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index 18.5-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe\n             daily)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033239", 
            "org_study_id": "NN1218-3887", 
            "secondary_id": [
                "2011-001580-41", 
                "U1111-1120-3772"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIAsp", 
                "description": "Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid\u00ae. Single dose of trial products will be administered subcutaneously (s.c. under the skin).", 
                "intervention_name": "insulin aspart (faster acting insulin aspart)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "description": "Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid\u00ae. Single dose of trial products will be administered subcutaneously (s.c. under the skin).", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 21, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the glucose infusion rate curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 12 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin aspart concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 12 hours"
            }, 
            {
                "measure": "Maximum glucose infusion rate", 
                "safety_issue": "No", 
                "time_frame": "Within 0 to 12 hours after dosing"
            }, 
            {
                "measure": "Maximum observed serum insulin aspart concentration", 
                "safety_issue": "No", 
                "time_frame": "Within 0 to 12 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}